Carocell Bio is a preclinical-stage biopharmaceutical company, focused on the development and commercialization of anti-inflammatory therapies and is committed to bringing novel, life-changing treatments to patients with atopic dermatitis, ulcerative colitis and other inflammatory conditions. Carocell Bio believes its portfolio of products, which combine peptides and nanoparticle delivery technology, has the potential to deliver efficacy and safety benefits over existing standards of care and provide new approaches in the treatment of inflammation.
Carocell is seeking a phased $10 million 'Series A' investment over the next 3 years to take the lead compound through to approved IND/CTA.
An initial $1 million investment will enable:
An additional $9 million investment will enable:
We are building a global pyramid of intellectual property (IP) protection
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902
Carocell Bio, Inc.
500 Delaware Avenue
Carocell Bio Ltd.
28a London Rd
Copyright Carocell Bio Ltd. ©2020